Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma

Urothelial carcinoma (UC) occupies a high incidence among all the genitourinary malignancies. Immune checkpoint inhibitors (ICIs), as alternative treatments of metastatic urothelial carcinoma (mUC), have been applied in the treatment of mUC after chemotherapy failure, with comparable efficacy and sa...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Di Wang, Kai Sun, Tianqi Wang, Dongxu Zhang, Fengze Sun, Yuanshan Cui, Hongwei Zhao, Jitao Wu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2021-11-01
coleção:	Frontiers in Pharmacology
Assuntos:	urothelial carcinoma (UC) immune checkpoint inhibitor (ICI) immune-related adverse events (irAEs) programmed cell death protein 1 (PD1) programmed cell death ligand protein 1 (PD-L1)
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2021.710943/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!